295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Growth of digital healthcare stabilised in 2023 The growth in the use of digital healthcare tools by care providers stabilised in 2023. This was mainly because most care providers were already using particular digital tools in 2022, such as the patient portal – on which patients can view the outcomes of examinations – and e-consultations (digital written contact with doctors).
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
Breast implants can cause health problems even five years or more after placement Over the past 5 years, the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI) has received 977 reports of health problems related to breast implants. An analysis by RIVM has shown that 39% of the reported health problems started 5 or more years after the implant’s placement.
No indication that investigated mesh implants used to treat pelvic organ prolapse are unsafe RIVM has conducted a laboratory study into six mesh implants from different manufacturers used in the Netherlands in 2018. The study revealed no indication that these products are unsafe for patients.
More attention needed for potential impact of drug waste on drinking water quality Drug waste contains substances that are harmful to the quality of drinking water. Because this waste is dumped illegally, these substances can end up in sources of drinking water.
Hypersensitivity reactions to fillers may occur after COVID-19 vaccination People may experience hypersensitivity reactions to fillers following a COVID-19 vaccination.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
Chromium-6 from medical implants not harmful to health Chromium-6 from medical implants, such as hip or knee implants, does not result in severe health damage.